Related Experiment Video
Updated: Jul 8, 2026
19:57
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
How antimalarial drug resistance affects post-treatment prophylaxis
1Mahidol-Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Rd,, Bangkok 10400, Thailand. nickw@tropmedres.ac
Malaria Journal
|January 12, 2008
Summary
Slowly eliminated antimalarial drugs provide post-treatment prophylaxis (PTP), preventing malaria reinfections. Drug resistance and pharmacokinetic properties influence PTP duration, requiring further study for optimal malaria control strategies.
Area of Science:
- Pharmacology
- Infectious Diseases
- Malariology
Background:
- Slowly eliminated antimalarial drugs offer a period of protection against malaria reinfection, known as post-treatment prophylaxis (PTP).
- The duration of PTP is influenced by drug dosage, pharmacokinetic profiles, and parasite susceptibility.
- Understanding PTP is crucial for malaria control, but its clinical benefits relative to preventing recrudescence require further evaluation.
Purpose of the Study:
- To assess the clinical benefits of preventing recrudescence versus preventing reinfection through PTP.
- To investigate the impact of antimalarial drug resistance on PTP duration.
- To explore the relationship between PTP duration and host immunity, particularly following intermittent preventive treatments.
Main Methods:
- Estimating the shortening of PTP due to drug resistance by analyzing in-vitro susceptibility and terminal elimination half-life during the drug's elimination phase.
- Reviewing existing data and identifying knowledge gaps regarding PTP following intermittent preventive treatments.
- Analyzing the interplay between PTP duration and the development of host immunity.
Main Results:
- Antimalarial drug resistance has been shown to shorten the duration of PTP.
- The degree of PTP shortening can be estimated based on in-vitro drug susceptibility and the drug's elimination half-life.
- Significant gaps in knowledge exist regarding PTP from intermittent preventive treatments and its interaction with immunity.
Conclusions:
- Further research is needed to fully understand the clinical implications of PTP compared to treatment efficacy.
- Estimating PTP duration is possible by considering drug resistance and pharmacokinetic factors.
- More data on PTP following intermittent preventive treatments and its relationship with immunity are essential for evidence-based malaria control policies.
Related Concept Videos
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.